《大行報告》大和:潤啤(00291.HK)昨日股價波動可能受資金流向影響 基本面未變
大和發表報告指,華潤啤酒(00291.HK)股價在2024年第一個交易日上午時段曾挫7%,可能是受資金流向影響,以及市場對其同行對2023年盈利預期的負面解讀,惟該行認爲華潤啤酒的基本面完整。
根據大和分析,潤啤去年銷量按年可能略有增長,意味着第四季的銷量按年增長約爲低單位數,12月份銷量按年降幅約爲低單位數,符合該行預期和公司指引,而次高端及以上產品的銷量在去年可能保持約20%的強勁增長,同時產品組合持續改善,平均售價也有所提高。因此潤啤仍是該行在中國啤酒行業的首選,評級「買入」,目標價48.5元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.